Citations

Clear

3942 citation(s) found for "To, Van".

Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline
Hembree, Wylie C., Cohen‐Kettenis, Peggy T. , Waal, Henriëtte A. Delemarre‐van de, Gooren, Louis , Meyer, Walter J. , Spack, Norman P. , Tangpricha, Vin , Montori, Víctor M. , Montori, Victor M , Tangpricha, Vin

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 9, 2009 | Volume: 94 | Issue: 9 | Pages: 3132-3154

10.1210/jc.2009-0345 | PMID 19509099 Get It

Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD)
Wider, Christian, Gerpen, Jay A. van, DeArmond, S. J., Shuster, Elizabeth A., Dickson, Dennis W. , Wszołek, Zbigniew K. , Dickson, Dennis W

Mayo Clinic

Neurology | June 1, 2009 | Volume: 72 | Issue: 22 | Pages: 1953-1959

10.1212/wnl.0b013e3181a826c0 | PMID 19487654 Get It

Histone Acetyltransferase CBP Is Vital To Demarcate Conventional and Innate CD8+ T-Cell Development
Fukuyama, Tomofusa , Kasper, Lawryn H., Boussouar, Fayçal , Jeevan, Trushar, Deursen, Jan van, Brindle, Paul K.

Mayo Clinic

Molecular and Cellular Biology | May 12, 2009 | Volume: 29 | Issue: 14 | Pages: 3894-3904

10.1128/mcb.01598-08 | PMID 19433445 Get It

Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium
Gaudet, Mia M., Cox, Angela , Camp, Nicola J. , Goode, Ellen L. , Humphreys, Manjeet K., Dunning, Alison M. , Giles, Graham G. , Severi, Gianluca , Baglietto, Laura , English, Dallas R. , Chang‐Claude, Jenny , Flesch‐Janys, Dieter, Abbas, Sascha, Salazar, Ramona, Mannermaa, Arto, Kataja, Vesa , Kosma, Veli-Matti, Lindblom, Annika , Margolin, Sara , Heikkinen, Tuomas , Kämpjärvi, Kati, Aaltonen, Kirsimari, Nevanlinna, Heli , Bogdanova, Natalia , Coinac, Irina, Schürmann, Peter , Dörk, Thilo , Bartram, Claus R., Schmutzler, Rita K., Tchatchou, Sandrine, Burwinkel, Barbara , Brauch, Hiltrud , Torres, Diana , Hamann, Ute, Justenhoven, Christina , Ribas, Gloría , Flyger, Henrik L., Peto, Julian , Fletcher, Olivia , Johnson, Nichola , dos‐Santos‐Silva, Isabel , Fasching, Peter A. , Beckmann, Matthias W. , Strick, Reiner , Ekici, Arif B. , Schmidt, Marjanka K. , Leeuwen, Flora E. van , Veer, Laura J. van’t , Southey, Melissa C. , Hopper, John L. , Apicella, Carmel, Haiman, Christopher A., Henderson, Brian E., Kolonel, Laurence N. , Kristensen, Vessela N. , Alnæs, Grethe Grenaker, Hunter, David J. , Cox, David G. , Hankinson, Susan E. , Seynaeve, Caroline, Tollenaar, Rob A.�E.�M. , Lissowska, Jolanta , Brinton, Louise A. , Pepłońska, Beata , Czene, Kamila , Li, Yuqing , Liu, Jianjun , Balasubramanian, Sabapathy P. , Rafii, Saeed , Reed, Malcolm , Pooley, Karen A. , Conroy, Don, Baynes, Caroline, Kang, Daehee , Yoo, Keun-Young, Noh, Dong‐Young , Ahn, Sei-Hyun, Shen, Chen‐Yang , Wang, Hui‐Chun , Yu, Jyh-Cherng, Wu, Pei-Ei, Ziogoas, Argyrios, Egan, Kathleen M. , Titus‐Ernstoff, Linda, Dietz, Amy Trentham, Sigurdson, Alice J., Bhatti, Parveen , Allen‐Brady, Kristina , Cannon‐Albright, Lisa , Wong, Jathine , Group, Australian Ovarian Cancer Study, Chenevix‐Trench, Georgia , Spurdle, Amanda B. , Beesley, Jonathan, Easton, Doug , García‐Closas, Montserrat , Thorne, Heather , Li, Yuqing , Milne, Roger L. , Morrison, Jonathan J. , Couch, Fergus J. , Olson, Janet E. , Wang, Xianshu , Mannermaa, Arto, Arias, José Ignacio , Benı́tez, Javier , Bojesen, Stig E. , Nordestgaard, Børge G. , Flyger, Henrik, Broeks, Annegien , Marchand, Loı̈c Le , Kraft, Peter , Vreeswijk, Maaike P.G. , Devilee, Peter , Chanock, Stephen Jacob , Hall, Per N , Anton‐Culver, Hoda , Newcomb, Polly A. , Alexander, Bruce H. , Group, Australian Ovarian Cancer Study, Pharoah, Paul D.P. , Nevanlinna, H , Dörk, Thilo , Giles, Graham G , Spurdle, Amanda B , Lissowska, Jolanta , Southey, Melissa C , English, Dallas R , Cannon-Albright, Lisa A , Dunning, Alison M , Cox, Angela , Torres, Diana , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Bhatti, Parveen , Czene, Kamila , Rafii, Saeed , Baglietto, Laura , Fletcher, Olivia , Brauch, Hiltrud , Lindblom, Annika , Liu, Jing , Kang, Daehee , Li, Yuqing

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 7, 2009 | Volume: 18 | Issue: 5 | Pages: 1610-1616

10.1158/1055-9965.epi-08-0745 | PMID 19423537 Get It

Abstract Previous studies have suggested that minor alleles for ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 may influence breast cancer risk, but the evidence is inconclusive due to their small sample size. These polymorphisms were genotyped in more than 30,000 breast cancer cases and 30,000 controls, primarily of European descent, from 30 studies in the Breast Cancer Association Consortium. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) as a measure of association. We found that the minor alleles for these polymorphisms were not related to invasive breast cancer risk overall in women of European descent: ECCR4 per-allele OR (95% CI) = 0.99 (0.97-1.02), minor allele frequency = 27.5%; TNF 1.00 (0.95-1.06), 5.0%; CASP10 1.02 (0.98-1.07), 6.5%; PGR 1.02 (0.99-1.06), 15.3%; and BID 0.98 (0.86-1.12), 1.7%. However, we observed significant between-study heterogeneity for associations with risk for single-nucleotide polymorphisms (SNP) in CASP10, PGR, and BID. Estimates were imprecise for women of Asian and African descent due to small numbers and lower minor allele frequencies (with the exception of BID SNP). The ORs for each copy of the minor allele were not significantly different by estrogen or progesterone receptor status, nor were any significant interactions found between the polymorphisms and age or family history of breast cancer. In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent. (Cancer Epidemiol Biomarkers Prev 2009;18(5):1610–6)
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
Tam, Constantine S. , Abruzzo, Lynne V. , Dyke, Daniel L. Van , Lynn, Alice, Keating, Michael J. , Shanafelt, Tait D. , Wierda, William G. , O’Brien, Susan , Ferrajoli, Alessandra , Lerner, Susan A. , Kay, Neil E. , Tam, Constantine S

Mayo Clinic

Blood | May 4, 2009 | Volume: 114 | Issue: 5 | Pages: 957-964

10.1182/blood-2009-03-210591 | PMID 19414856 Get It

To determine the clinical fate of patients with de novo deletion 17p13.1 (17p−) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p− CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p− in 25% or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95%, 74%, and 22%, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50%, 72%, and 81%, respectively. Patients with 17p− CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
Verwey, Nicolaas A. , Flier, Wiesje M. van der , Blennow, Kaj , Clark, Christopher M. , Sokolow, Sophie , Hartmann, Tobias , Kapaki, E. , Lannfelt, Lars , Parnetti, Lucilla , Petzold, Axel , Pirttilä, Tuula, Saleh, Lanja , Skinningsrud, Anders, Swieten, John C. van , Wiltfang, Jens , Younkin, Steve, Scheltens, Philip , Blankenstein, Marinus A. , Deyn, Peter Paul De , Galasko, Douglas , Hampel, Harald , Mehta, Pankaj D , Verbeek, Marcel M. , Parnetti, Lucilla , van der Flier, Wiesje M , Scheltens, Philip , Wiltfang, Jens , Van Swieten, John C

Mayo Clinic

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine | April 23, 2009 | Volume: 46 | Issue: 3 | Pages: 235-240

10.1258/acb.2009.008232 | PMID 19342441 Get It

Background Different cerebrospinal fluid (CSF) amyloid-beta 1–42 (A β 1–42 ), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres. Methods Three CSF-pool samples were distributed to 13 laboratories in 2004 and the same samples were again distributed to 18 laboratories in 2008. In 2004 six laboratories measured A β 1–42 , Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex. Results In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for A β 1–42 , Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotest ® ( N = 13) for A β 1–42 , lower interCV were calculated (22%). The centres that participated in both years ( N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008. Conclusions The highest variability was found for A β 1–42 . The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.
Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia
Braggio, Esteban , Keats, Jonathan J. , Leleu, Xavier , Wier, Scott Van, Jiménez‐Zepeda, Víctor H. , Valdez, Riccardo, Schop, Roelandt F.J., Price-Troska, Tammy, Henderson, Kimberly J., Sacco, Antonio , Azab, Feda, Greipp, Philip R., Hayman, Suzanne R. , Rajkumar, S. Vincent , Carpten, John D. , Chesi, Marta , Barrett, Michael T. , Stewart, A. Keith, Bergsagel, P. Leif , Fonseca, Rafaël , Gertz, Morie A. , Doǧan, Ahmet , Ghobrial, Irene M. , Bergsagel, P. Leif , Rajkumar, S Vincent , Braggio, Esteban , Keats, Jonathan J , Fonseca, Rafael

Mayo Clinic

Cancer Research | April 7, 2009 | Volume: 69 | Issue: 8 | Pages: 3579-3588

10.1158/0008-5472.can-08-3701 | PMID 19351844 Get It

Abstract Waldenström's macroglobulinemia (WM) is a distinct clinicobiological entity defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in bone marrow (BM) and IgM paraprotein production. Cytogenetic analyses were historically limited by difficulty in obtaining tumor metaphases, and the genetic basis of the disease remains poorly defined. Here, we performed a comprehensive analysis in 42 WM patients by using a high-resolution, array-based comparative genomic hybridization approach to unravel the genetic mechanisms associated with WM pathogenesis. Overall, 83% of cases have chromosomal abnormalities, with a median of three abnormalities per patient. Gain of 6p was the second most common abnormality (17%), and its presence was always concomitant with 6q loss. A minimal deleted region, including MIRN15A and MIRN16-1, was delineated on 13q14 in 10% of patients. Of interest, we reported biallelic deletions and/or inactivating mutations with uniparental disomy in tumor necrosis factor (TNF) receptor–associated factor 3 and TNFα-induced protein 3, two negative regulators of the nuclear factor-κB (NF-κB) signaling pathway. Furthermore, we confirmed the association between TRAF3 inactivation and increased transcriptional activity of NF-κB target genes. Mutational activation of the NF-κB pathway, which is normally activated by ligand receptor interactions within the BM microenvironment, highlights its biological importance, and suggests a therapeutic role for inhibitors of NF-κB pathway activation in the treatment of WM. [Cancer Res 2009;69(8):3579–88]
The Osteogenic Transcription Factor Runx2 Controls Genes Involved in Sterol/Steroid Metabolism, Including Cyp11a1 in Osteoblasts
Teplyuk, Nadiya M., Lou, Yang , Hawse, John R. , Hassan, Mohammad Q., Teplyuk, Viktor I., Pratap, Jitesh , Galindo, Mario , Stein, Janet L. , Stein, Gary S., Lian, Jane B. , Wijnen, André J. van , Zhang, Ying , van Wijnen, Andre J

Mayo Clinic

Molecular Endocrinology | April 3, 2009 | Volume: 23 | Issue: 6 | Pages: 849-861

10.1210/me.2008-0270 | PMID 19342447 Get It

Molecular evolution of the junctophilin gene family
Garbino, Alejandro , Oort, Ralph J. van, Dixit, Sayali S., Landstrom, Andrew P. , Ackerman, Michael J. , Wehrens, Xander H.T. , Landstrom, Andrew P , Wehrens, Xander H T

Mayo Clinic

Physiological Genomics | March 25, 2009 | Volume: 37 | Issue: 3 | Pages: 175-186

10.1152/physiolgenomics.00017.2009 | PMID 19318539 Get It

Junctophilins (JPHs) are members of a junctional membrane complex protein family important for the physical approximation of plasmalemmal and sarcoplasmic/endoplasmic reticulum membranes. As such, JPHs facilitate signal transduction in excitable cells between plasmalemmal voltage-gated calcium channels and intracellular calcium release channels. To determine the molecular evolution of the JPH gene family, we performed a phylogenetic analysis of over 60 JPH genes from over 40 species and compared conservation across species and different isoforms. We found that JPHs are evolutionary highly conserved, in particular the membrane occupation and recognition nexus motifs found in all species. Our data suggest that an ancestral form of JPH arose at the latest in a common metazoan ancestor and that in vertebrates four isoforms arose, probably following two rounds of whole genome duplications. By combining multiple prediction techniques with sequence alignments, we also postulate the presence of new important functional regions and candidate sites for posttranslational modifications. The increasing number of available sequences yields significant insight into the molecular evolution of JPHs. Our analysis is consistent with the emerging concept that JPHs serve dual important functions in excitable cells: structural assembly of junctional membrane complexes and regulation of intracellular calcium signaling pathways.
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study
Song, Honglin , Ramus, Susan J. , Kjær, Susanne K. , DiCioccio, Richard A., Chenevix‐Trench, Georgia , Pearce, Celeste Leigh, Høgdall, Estrid , Whittemore, Alice S. , McGuire, Valerie , Høgdall, Claus , Blaakær, Jan , Wu, Anna H. , Berg, David J. Van Den, Menon, Usha , Jacobs, Ian , Webb, Penny M., Beesley, Jonathan, Chen, Xiaoqing, Group, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study, Rossing, Mary Anne, Chang‐Claude, Jenny , Wang‐Gohrke, Shan , Goodman, Marc T. , Lurie, Galina, Thompson, Pamela J., Carney, Michael E., Ness, Roberta B., Moysich, Kirsten B., Goode, Ellen L. , Vierkant, Robert A. , Cunningham, Julie M. , Anderson, S. Keith , Schildkraut, Joellen M. , Iversen, Edwin S., Moorman, Patricia G. , García‐Closas, Montserrat , Lissowska, Jolanta , Brinton, Louise A. , Ponder, Bruce A.J., Easton, Douglas F. , Gayther, Simon A. , Pharoah, Paul D.P., Webb, Penelope M. , Bowtell, David D.L. , Stram, Daniel O. , Gentry‐Maharaj, Aleksandra , Webb, Penny M., Chen, Xiaoqing, Group, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study, Doherty, Jennifer A. , Berchuck, Andrew , Chanock, Stephen Jacob , Anton‐Culver, Hoda , Ziogas, Argyrios , Brewster, Wendy R. , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Human Molecular Genetics | March 20, 2009 | Volume: 18 | Issue: 12 | Pages: 2297-2304

10.1093/hmg/ddp138 | PMID 19304784 Get It